MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.

About Opthea

Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.

Authorized for release to ASX by Fred Guerard, CEO

Investor Enquiries

PJ Kelleher
LifeSci Advisors
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579

Media

Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399
Email: info@opthea.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.